Search Results

Envisagenics announced the publication in the journal Molecular Systems Biology of study results evaluating the company’s SpliceCore AI/ML platform in Triple Negative Breast Cancer.

Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire State Development and Red Cell Partners, and new strategic investor Bristol Myers Squibb (NYSE: BMY).

Envisagenics today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY).

Envisagenics , an Artificial Intelligence (“AI”)-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Cancer Research Horizons, Cancer Research UK’s innovation engine, and Queen Mary University of London.

Envisagenics, Inc. announced that it was awarded a Small Business Innovation Research Direct to Phase II grant from the National Cancer Institute, part of the National Institutes of Health.

Envisagenics secured Series A financing to scale its drug discovery platform and biopharmaceutical partnerships.

Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases.

Envisagenics, a company developing therapeutics for RNA splicing errors that often lead to genetic disorders including cancer, announced today that it has entered into a research program agreement with the Lung Cancer Initiative (LCI) at Johnson & Johnson.

Envisagenics, Inc., a New York-based biotechnology company leveraging artificial intelligence (AI) and RNA-splicing analytics for discovery and development of disease specific therapeutics, announced today that it was awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

Dynamk Capital invested $500,000 in Envisagenics, leading the $2.25M seed round alongside other investors.